In studies reviewed by the FDA, Leqembi appeared to slow declines in memory and thinking by about 27% after 18 months of treatment. It also dramatically reduced the sticky beta-amyloid plaques that tend to build up in the brains of people with Alzheimer's.
The drug-shortage crisis is not just a supply chain issue, but also a quality-management crisis with life-and-death implications. These crises are driven by poor supply chain coordination and market failure. And the U.S. Food and Drug Administration is a root cause—and could be a key solution.